Insight

Petros Grivas/fredhutch.org

Feb 13, 2025, 09:30

Petros Grivas: TROPiCS04 P3 trial data has been published

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared an article he and his colleagues authored on X:

“We just published TROPiCS04 P3 trial data

Annals of Oncology with Tom Powles, Y. Loriot, Scott Tagawa et al.

Primary OS endpoint was not met, higher ORR with SG (23%) vs taxane/vinflunine (14%), G-CSF primary prophy only ~20% ->G5 neutropenic events on SG.”

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Authors: Tom Powles et al.

Petros Grivas

A. Necchi C. Vulsteke C.N. Sternberg C.S. Sima cancer F. Boateng I. Durán J. Bellmunt J. Guo J. Waldes L. Wang M. De Santis M. Gross-Goupil M. Kovalenko M. Sierecki OncoDaily Oncology P. Grivas P.J. Goebell Petros Grivas R. Morales-Barrera S. Tagawa S.H. Park T. Powles Tom Powles Y. Loriot

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%